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Abstract
Influenza A virus seasonal outbreaks and occasional pandemics represent a global health threat. The high genetic instability
of this virus permits rapid escape from the host immune system and emergence of resistance to antivirals. There is thus an
urgent need to develop novel approaches for efficient treatment of newly emerging strains. Based on a sequence alignment
of representatives from every subtype known to infect humans, we identified nucleic acid regions that are conserved
amongst these influenza A populations. We then engineered SOFA-HDV-Ribozymes as therapeutic tools recognizing these
conserved regions to catalytically cleave the corresponding viral mRNA targets. The most promising ribozymes were chosen
based on an initial in silico screening, and their efficacy was assessed using in vitro cleavage assays. Further characterization
of their antiviral effect in cell culture and in mice led to the gradual identification of prophylactic SOFA-HDV-Ribozyme
combinations, providing proof-of-principle for the potential of this novel strategy to develop antivirals against genetically
highly variable viruses.
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Introduction
Influenza A virus belongs to the Orthomyxoviridae family, and its
genome consists of eight fragments of single-stranded RNA of
negative polarity. The annual seasonal outbreaks as well as
occasional pandemics constitute major public health threats.
During a typical influenza season, 5–15% of the population in
the United States is infected, causing 3 to 5 million people to suffer
from severe illness. Major genetic changes in the circulating strain
can result in global pandemics, which have happened three times
in the 20
th century, with the most devastating pandemic killing
over 40 million people in 1918–1919 [1]. Influenza pandemics
remain a constant threat because of the unpredictability of the
timing, the nature, and the virulence of the next major antigenic
shift or drift [2–4].
Currently, the annual vaccine containing the predicted
predominant strains represents the most effective tool for influenza
control. Unfortunately, the high genetic variability of the virus
renders the protection incomplete. In the case of a newly emerging
strain, vaccination is only available a few months after the first
appearance, leaving the population vulnerable during the crucial
early phase of a pandemic. There are several influenza-specific
antiviral drugs available, namely neuraminidase inhibitors and
M2-ion channel blockers, which can be associated with important
gastrointestinal and sometimes neurological side effects [2,5–7].
Furthermore, drug-resistant strains have emerged and rapidly
spread during the last years [8–10]. New antiviral strategies based
on RNA interference show encouraging effectiveness both in cell
cultures and in animal models [11–18]. However, problems of
potency, specificity, and/or cell type-dependent responses illus-
trate a lack of understanding of the intracellular mechanisms
involved. Moreover, the high sequence specificity of siRNAs
reduces their potential to efficiently target newly emerging strains.
There is therefore an important need for the development of new
strategies that display broad-spectrum properties against new
influenza strains that arise through antigenic shift or drift.
Ribozymes are RNA molecules that possess catalytic activity,
and both artificial and naturally occurring ribozymes function
efficiently in human cells [19–22]. The hepatitis delta virus
ribozyme (HDV-Rz) is derived from a natural motif found in
HDV. Based on sequence complementarity, this ribozyme can
specifically recognize and subsequently catalyze the cleavage of
target RNA molecules. Its full activity under physiological
conditions and outstanding stability in vivo makes it particularly
attractive for the development as a therapeutic tool [23,24].
Molecular engineering has led to the improvement of the HDV-
Rz catalytic motif through the addition of a specific on/off adapter
(SOFA) module, which increases the accuracy of the cleavage
while reducing the cleavage of non-specific targets [25]. The
resulting SOFA-HDV-Rz has already been successfully used in
human cells to target and discriminate between closely related
mRNAs [26,27].
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control influenza, we initially identified conserved target sequences
in all subtypes known to infect the human population for six out of
eight influenza collinear mRNAs, and generated a total of 45
candidate SOFA-HDV-Rz. The step-by-step screening strategy,
consisting of both in vitro and cellular cleavage assay and in cellulo
replication survey, led to the identification of efficient SOFA-
HDV-Rz that were further characterized for their antiviral activity
in an influenza mouse model.
Results
Conserved SOFA-HDV-Rz targets are present in six
influenza segments
Even though the emergence of new influenza viruses is highly
likely, the exact subtype and antigenic characteristics are currently
impossible to predict. We therefore intended to identify regions in
the viral mRNAs which are conserved in all subtypes that have the
potential to cause disease in humans. Towards this, a bioinfor-
matics analysis was conducted with complete genome sequences of
20 arbitrarily chosen isolates available in the NCBI Influenza
Virus Resource database for each of the following subtypes:
H1N1, H1N2, H2N2, H3N2, H5N1, H7N3, and H9N2. The
sequences of each mRNA segment were aligned, and the degree of
homology for the first 1000 nucleotides of each fragment was
defined, since targeting the 59 region of an mRNA is more likely to
result in transcript fragments that can no longer encode a
functional protein. Consistent with the high genetic variability of
the viral glycoproteins [4,28], neither the hemagglutinin (HA) nor
the neuraminidase (NA) segments contained any conserved
regions, while several conserved regions of sufficient size to be
potential SOFA-HDV-Rz targets were identified for the other six
segments (Figure 1).
SOFA-HDV-Rz are designed to contain three specific domains
for a selected target: a blocker domain, which locks the catalytic
core in an inactive conformation; a biosensor, which removes the
block upon recognition of the target; and a P1 domain which
binding results in cleavage of the targeted RNA (Figure 2). The
SOFA module acts through the binding of the blocker on the P1
domain [25]: this short duplex increases the energetic barrier for
non-specific interactions with substrates. The biosensor offers an
extended base-pairing favouring interaction with the genuine
substrate; this longer duplex disrupts the hindrance carried out by
the blocker and therefore allows the P1 accessibility for elongated
substrate binding and subsequent target cleavage. Screening of the
conserved regions for the appropriate target sequences (HG*N*6-
N3-6-N*9-12: H=A, C or T; N=A, T, G or C; *=conserved nt)
yielded more than 45 potential SOFA-HDV-Rz. These candidates
were then analyzed for possible off-targeting of cellular mRNAs
using the RiboSubstrate software [29]. Only SOFA-HDV-Rz
displaying a high level of specificity towards influenza mRNAs
with a low probability of interactions with cellular mRNAs were
retained for further investigation. The predicted specificity for
each SOFA-HDV-Rz is shown in Table S1.
A subset of SOFA-HDV-Rz shows catalytic activity
To assess the ability of the selected SOFA-HDV-Rz to target
specific influenza mRNA transcripts, the cleavage efficacy of
radiolabeled in vitro synthesized H1N1 A/USSR/90/77 mRNAs
was tested under single-turnover conditions ([Rz].[S]) and
analyzed on a denaturant polyacrylamide gel. Two active
ribozymes were found to cleave the 59 regions of both PB2 and
PB1 mRNAs. The mRNA of PA was targeted by 11 SOFA-HDV-
Rz while three different ribozymes were able to cleave both the
Figure 1. Representation of the conservation study performed
on the viral mRNA fragments from human influenza A virus. For
each of the 8 influenza mRNA fragments (PB2, PB1, PA, HA, NP, NA, M,
NS), up to 20 nucleic acid sequences from the 7 human strains (H1N1,
H1N2, H2N2, H3N2, H5N1, H7N3 and H9N2) were randomly selected
and aligned to calculate a conservation rate at each position. The color
gradation schematically identifies the level of conservation found in the
first 1000 nucleotides of the different viral mRNAs. The arrows indicate
the position of the most efficient ribozymes (see Table 1).
doi:10.1371/journal.pone.0027327.g001
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the seven ribozymes selected against the NS mRNAs displayed
catalytic activity (Figure 3A and Table 1). The SOFA-HDV-Rz-
NS-527a was the most catalytically efficient molecule, displaying
75% cleavage of the viral NS RNA substrate. Overall, this assay
yielded a collection of 26 SOFA-HDV-Rz that efficiently cleave
the collinear mRNAs produced from the six remaining influenza
segments.
Several candidates SOFA-HDV-Rz retain activity in a
cellular environment
To confirm the catalytic activity of the selected SOFA-HDV-Rz
in a cellular environment, plasmids were designed to simulta-
neously express a SOFA-HDV-Rz and the corresponding target
mRNA. SOFA-HDV-Rz were under the control of a cellular
RNA polymerase III promoter, while viral mRNAs were expressed
using a Tet-inducible Pol II promoter (Figure S1). We generated a
HEK-293 cell line stably expressing the Tet-responsive transacti-
vator, which supports activation of that promoter by doxycycline.
That modified cell line was transfected with the dual vector
expressing both the viral RNA and the corresponding SOFA-
HDV-Rz.
Target mRNA expression was first detected after 4 h and
peaked around 20 h after doxycycline induction (data not shown).
To assess cleavage efficacy, total cellular RNA was extracted and
analyzed by ribonucleic protection assay (RPA) using specific
probes for each target mRNA as well as GAPDH and zeoR
mRNA for cellular RNA and plasmid controls, respectively.
Results were confirmed by Northern blot hybridization. The
reduction in target mRNA levels remained constant between 4 h
and 20 h of induction, i.e. at low and high target abundance. Of all
the SOFA-HDV-Rz that showed activity for their respective
synthetic target RNA, only one candidate retained activity in the
cellular context for PB1, PB2, and the NP, while two candidates
Figure 2. Schematic drawing of a SOFA-HDV-Rz. The yellow box
indicates the SOFA module. The biosensor and the blocker are
illustrated in green and red, respectively. The bold arrow indicates
the cleavage site. S, P1, and P1.1 stand for the substrate, P1 recognition
stem, and the P1.1 pseudoknot, respectively. Without the appropriate
substrate, the cleaving activity of the SOFA-HDV-Rz is locked by the
base pairing of the blocker (4 nts) on the P1 recognition sequence (OFF
state). Upon recognition of its specific target, the biosensor (10–12 nts)
of the SOFA module base pairs on the substrate downstream of the
cleavage site, which disrupts the interaction of the blocker on the P1
recognition sequence and therefore allows the formation of the P1
stem (7 nts) between the ribozyme and the substrate (ON state). This
leads to the specific cleavage of the RNA substrate.
doi:10.1371/journal.pone.0027327.g002
Figure 3. Catalytic activity of SOFA-HDV-Rz directed against
influenza mRNAs. The identity of the SOFA-HDV-Rz tested, which
contains the target name followed by a number indicating the cleavage
site and a lower case when more than 1 ribozyme targets the same site,
is listed above the gels. A negative control (No Rz) was performed in the
absence of any SOFA-HDV-Rz. (A) 39-radiolabeled RNA substrate
consisting of the influenza NS mRNA was incubated with a SOFA-
HDV-Rz at 37uC for 2 h in presence of magnesium in Tris-HCl buffer
pH 7.5. The reaction products were separated on PAGE and visualized
by phosphorimaging. The positions of the substrate and 39 end product
are indicated. (B) Ribonucleic protection assay on total cell extract
prepared from Tet-modified HEK-293 cells transfected with pDUAL-JU
expressing both the NS target (induced for 20 h) and the SOFA-HDV-Rz.
The bands corresponding to the substrate mRNA are normalized with
Zeo
R reference mRNA from the pDUAL-JU vector. The levels of Zeo
R and
NS mRNAs are presented in the upper and lower panel, respectively.
doi:10.1371/journal.pone.0027327.g003
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and four of the NS-specific SOFA-HDV-Rz remained active
(Figure 3B). It should be noted that one NS-specific ribozyme
(SOFA-HDV-Rz-NS-527b) could not be assayed since its primary
sequence encompasses a Pol III stop signal. For all the SOFA-
HDV-Rz that exhibited a significant cleavage activity, a P1.1
inactive mutant, which consists in replacing the nucleotides
forming the pseudoknot I.I (i.e. including two GC bp) by for 4
adenosines, was constructed. These substitutions prevent the
formation of the pseudoknot I.I, a crucial step in the folding
pathway, thereby inhibiting its catalytic activity [30,31]. Using
such controls, we observed in most of the cases a reduction in the
overall levels of the targeted mRNAs in cellular assays (data not
shown) that most likely results from antisense effect, since those
mutants retain the ability to fully bind the target. For example, the
active and inactive SOFA-HDV-Rz-NP-804 displayed a 38% and
24% reduction of the target mRNA, respectively. More impor-
tantly, the reductions observed with the active ribozymes were
more significant than their respective inactive version in all cases
(data not shown), supporting that they resulted from the cleavage
action.
Combined SOFA-HDV-Rz displays antiviral activity
To evaluate the antiviral activity of the catalytically active
SOFA-HDV-Rz, we established a flow cytometry-based assay
allowing us to quantify the proportion of infected cells. Toward
this, Madin-Darby canine kidney (MDCK) cells, which are
naturally susceptible to influenza infection, were first transfected
with SOFA-HDV-Rz encoding plasmids and then infected with
H1N1 A/Puerto Rico/8/34 (PR8) at a multiplicity of infection
(MOI) of 0.1. An antibody against the HA protein was chosen to
ensure an unbiased detection of infected cells, since none of the
ribozymes target this particular glycoprotein. Moreover, combi-
nations of two SOFA-HDV-Rz targeting the same or different
viral mRNAs were transfected simultaneously. Ten hours after
infection, around 30% of the non-treated cells expressed the HA
protein (Figure 4A). While no improvement was seen for the
combination of PA- and NS-targeting ribozymes, both the SOFA-
HDV-Rz-M-172a/-M-226b and -NS-541/-NP-804 pairs resulted
in a small reduction in the number of HA-positive cells (Figure 4A).
No significant effect was observed for individually transfected
ribozymes (data not shown).
Only the NS/NP combination retains antiviral activity in
vivo
The previous result does not provide any information on the
actual number of viral particles produced in the presence of active
ribozymes. It only indicates that a smaller number of infected-cells
are actually detected in the presence of certain ribozyme
combinations. Considering that a partial reduction of viral titer
can potentially cause a significant decrease in disease severity since
the immune system contributes importantly to the control of
influenza replication and spread in vivo, we further investigated the
extent of morbidity reduction and viral inhibition by the SOFA-
HDV-Rz combinations in a mouse model. To validate the in vivo
transfection protocol, mice were initially transfected intranasally
with an eGFP expression plasmid using In Vivo-JetPEI as
transfection agent. Twenty-four hours later, eGFP expression
was detected throughout the lower respiratory tract, confirming
efficient delivery to the site of influenza infection (data not shown).
To assess in vivo efficacy, the different SOFA-HDV-Rz combina-
tions were instilled intranasally, followed by infection with 10
5
50% tissue culture infectious doses (TCID50) of PR8 6 h later.
Considerable variability of clinical disease severity was observed in
Table 1. In vitro catalytic activity of the selected SOFA-HDV-
Rz.
Target SOFA-HDV-Rz P1 BS Cleavage %*
PB2 PB2-177 AUCAUCU GGAUAUUUCAU 20
PB2-324a UUCCACU GGUCCAUU 15
PB2-324b UUCCACU GGUCCAUUUC 7
PB1 PB1-132a CCAUGGU GUAUCCUGUUCC ,1
PB1-132b CCAUGGU AUCCUGUUCC ,1
PB1-167a UGUUGAU UAUUGGUGUG 25
PB1-167b UGUUGAU UGAAUAUUGGUG ,1
PB1-296 CACAAUU GCCAUUGCUUC 57
PB1-907 GGUCAUU GUGUCCUGAG ,1
PA PA-134a AUAUUGU UCCAAGUGAG 38
PA-134b AUAUUGU ACCUCCAAGUG 41
PA-612a UCGCCUU CUUCAAUUGU 28
PA-612b UCGCCUU UUUCUUCAAUUG 33
PA-629 UUUCUUU CCUGUGAUUUCA 49
PA-714 UAGGCUU CGAAUCCAUC 51
PA-716 CAUAGGU UUCGAAUCCA 54
PA-722a CAUCCAU CCGUUCGGUU 42
PA-722b CAUCCAU CCGUUCGGUUCG 43
PA-724a UCCAUCU CGUUCGGUU 38
PA-724b UCCAUCU AGCCGUUCGG 22
PA-752a UGCCCUU GACAUUUGAGAA 9
PA-752b UGCCCUU ACAUUUGAGA 11
PA-754 CUUGCCU UGGACAUUUG ,1
PA-876a AUCCAUU AUGCUUAAUUUU ,1
PA-876b AUCCAUU AAUGCUUAAUU ,1
NP NP-59 UGGUGCU GUUCAUAAGAC ,1
NP-173a GGUGCAU CACUGAGUUU 52
NP-173b GGUGCAU CUGAGUUUAAG 50
NP-710a GUUGCAU UUUCCUUUGA ,1
NP-710b GUUGCAU AAUUUUCCUUU ,1
NP-744 UUUGUGU UGAUCCAUCAUU ,1
NP-804 GAUCUUU AGUGCCAGAAA 54
M M-172a UCUUGUU GAGGUGACAG 23
M-172b UCUUGUU GAGGUGACAGGA 16
M-226a ACUGGGU ACGCUGCAGUCC 7
M-226b ACUGGGU GCAGUCCUCG 24
M-231a CGCUCAU CUACGCUGCAG ,1
M-231b CGCUCAU CGUCUACGCUGC ,1
NS NS-110 GGGCAUU AGCCGAUCAAG ,1
NS-128 CGAAGCU GGGACUUGAUC 34
NS-527a UAUGUCU GACAUCCUCA 75
NS-527b UAUGUCU UUUGACAUCC 54
NS-541 GACAUCU CCAAUUGCAU 52
NS-622a GAAUCUU CUGCUUCUCC 31
NS-622b GAAUCUU ACUGCUUCUC 13
*Margin of error on the cleavage rate is 10%.
doi:10.1371/journal.pone.0027327.t001
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Rz-PA-714/-PA-722a, -PB1-167a/-PB2-177, and -NS-527a/NS-
622a combinations, while all animals in the –M-172a/-M-226b
and -NS-541/-NP-804 treated groups were protected from severe
disease and death (Figure 4B). Mice transfected with the SOFA-
HDV-Rz-NS-541/-NP-804 combination displayed especially low-
er clinical scores than the average controls. To examine the direct
inhibitory effect on virus replication, animals were transfected with
the same SOFA-HDV-Rz combinations, followed by infection
with PR8 after 6 h and sacrifice 24 h after infection. Quantifica-
tion of viral titers in lung tissue revealed that only the SOFA-
HDV-Rz-NS-541/-NP-804 combination significantly inhibited
virus replication at early times after infection, with up to 1000-
fold reduction in viral titer seen in some individuals (Figure 4C).
Discussion
We have developed a step-by-step strategy to achieve efficient
and affordable selection of therapeutic molecules against con-
served regions of a broad range of influenza A subtypes. This
strategy capitalizes on an in silico analysis of all subtypes known to
infect the human population, allowing an inexpensive and time-
saving identification of regions that are conserved over time and
regardless of reassortments. We designed SOFA-HDV-Rz to
target those identified regions and catalytically cleave the mRNA,
which are subsequently degraded by the host cellular machinery.
The most promising candidates were further evaluated first in in
vitro assays to assess catalytic activity, and then regarding their
antiviral activity in cell culture and in vivo, yielding two
combinations with promising prophylactic activity. Our study
thus provides proof-of-principle for the identification of candidate
HDV-SOFA-Rz with antiviral activity against a highly variable
RNA virus.
The lack of proof-reading capacity of the viral polymerase, the
high replication rate and short replication time are the cause of the
high genetic variability inherent to RNA viruses, unless there is
functional pressure to maintain specific nucleotides [28,32]. The
extensive in silico conservation study, which to our knowledge is the
first of its kind, allowed the identification of several such stretches
of conserved nucleotides sufficiently long for efficient SOFA-
HDV-Rz targeting in all but the two viral mRNAs coding for the
viral glycoproteins NA and HA. These two major surface
glycoproteins are highly variable due to the continuous antigenic
pressure [4,28,33] and were thus excluded from the study.
Therapeutic molecules targeting regions identified through this
process are thus expected to display broad-spectrum specificity
and are likely to retain efficacy against new strains, thereby
Figure 4. Antiviral activity of SOFA-HDV-Rz (A) in cells and (B
and C) in vivo. (A) MDCK cells were transfected with the indicated
SOFA-HDV-RZ combinations, and infected with PR8 at a MOI of 0.01
after 24 h. Ten hours later, the cells were fixed and stained with a
monoclonal antibody against HA. The percentage of HA-positive cells
detected in three independent experiments is shown. Error bars
indicate standard deviation. (B and C) BALB/c mice were transfected
intranasally with the indicated SOFA-HDV-Rz combinations and
challenged with 10
5 50% tissue culture infectious doses (TCID50)o f
PR8 6 h later. (B) Clinical score on day 3 after infection. The clinical score
represents a combination of posture, activity, and weight loss scores
evaluated on a 0-1-2 scale as detailed in materials and methods. Results
from 2 independent experiments are shown, and each symbol
represents one animal. (C) Viral lung titers on day 1 after infection.
Animals were sacrificed 24 h after infection and the lung was harvested.
Titers are expressed as TCID50 per g of tissue. Student’s t-test : asterisk,
P,0.05; three asterisks, P,0.001.
doi:10.1371/journal.pone.0027327.g004
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nucleotide sequences [19,34–36].
The HDV-Rz is one of the rare examples derived from an RNA
species found to infect human cells, therefore being naturally
optimized to fully function in physiological conditions [23,24]. A
SOFA module has been engineered to improve its catalytic
characteristics, greatly increasing its fidelity [25]. The in vitro
activity of many SOFA-HDV-Rz designed to target conserved
regions identified with the bio-informatics of six collinear viral
mRNA was evaluated, as targeting the viral mRNA might be more
effective than the genomic RNA due to its higher abundance and
lack of encapsidation by the NP protein [36]. Since RNA
molecules can have long-range interactions, working with in vitro
synthesized full-length target RNA is likely to be an accurate way
to evaluate the potential of the effective candidates in regards of
the tridimensional accessibility. Roughly half of the potential
candidates showed appreciable catalytic activity, which is in the
same range as other studies done with long RNA and SOFA-
HDV-Rz [27,37,38]. The ineffectiveness of the rejected candidates
could be explained either by inaccessibility of the target RNA or
by kinetic trapping of the SOFA-HDV-Rz in an inactive
conformation, which could be attributed to diverse interaction
between different parts of the molecule. In particular, the
biosensor interaction with the J4/2-P2 region (Figure 2) is known
to inhibit the catalytic activity. Such example is found in the
SOFA-HDV-Rz-NP-710a and its 7 consecutive nts that could be
base-paired with that area. An elevated blocker strength is also
detrimental for the release of the P1 and successive substrate
recognition. This situation is found in SOFA-HDV-Rz-PB1-132a
and -PB1-132b that have an elongated blocker (from the
continuous biosensor nts) of 6 nts containing 4 strong G-C bonds.
With the high potential of this novel class of therapeutic ribozyme,
it would be of great interest to learn which criteria could
discriminate between an intrinsically functional or inactive SOFA-
HDV-Rz. The information gathered from the SOFA-HDV-Rz
panel produced in this project is currently under investigation to
develop new screening and selection criteria to improve the yield
of active molecules in future studies.
Around half of the catalytically active SOFA-HDV-Rz failed to
display sufficient activity in cellular assays, either due to a
differential reaching of the target (divergent conformation or
protection through interaction with host factors) or to an inhibited
state of the ribozyme. The observed effect of the active candidates
is necessarily the sum of antisense and cleavage action, leading to
the development of powerful antisense-enhanced ribozymes
[19,39]. However, the antisense effect in some cases was really
minimal while all ribozymes were shown to actively cleave the
mRNAs, although at different levels. The use of certain
combinations of ribozymes clearly reduces the probability of
generating escape mutants [35,40]. Therefore, combinations of
SOFA-HDV-Rz chosen from the collection of catalytically active
molecules were tested for their antiviral effect in infected cells.
While most of the combinations targeting the same RNA showed
no increase in activity, all the SOFA-HDV-Rz duos targeting
different viral mRNAs inhibited viral growth, indicating a synergic
effect. However, it is too early in our investigation to comment on
how the synergic effect precisely takes place and/or on the steps of
the viral replication cycle that are the most affected by the action
of the ribozyme. The slight decrease of infected cells in the
replication assays is explained by the sorting system which scores
positive for an infected cell independently of its viral titer
(Figure 4A). The efficient SOFA-HDV-Rz combinations also
reduced viral replication in lungs and protected animals from
severe illness, whereas combinations that were unable to inhibit
viral replication in cell culture had no beneficial effect in vivo. The
SOFA-HDV-Rz NS-541/NP-804 duo led to a one order
magnitude difference in peak lung titers, which is in a range
previously shown to correlate with decreased disease severity [36].
It will be of great interest to investigate further combinations and
to extend the clinical evaluation to post-exposure treatment in
order to gain insight in the curative prospect of SOFA-HDV-Rz.
Respiratory viruses such as influenza A are ideal target for nucleic
acid therapy since the upper airways and even lungs are relatively
accessible for gene delivery systems [36].
In summary, our study constitutes a proof-of-principle for a new
strategy to find therapeutic molecules against highly variable RNA
viruses using influenza A as a prototype. Our approach offers an
inexpensive and time-saving way for the development of any RNA
recognition-based design, starting with the identification of
conserved nucleic acid regions by in silico analysis. A step-by-step
selection strategy with increasing stringency from in vitro catalytic
cleavage evaluation to in vivo efficacy assessment yielded a panel of
SOFA-HDV-Rz that target influenza A virus mRNAs. This
innovative system led to the identification of potent SOFA-HDV-
Rz against which emergence of resistance would be unlikely giving
the conserved nature of the targeted nucleotides.
Materials and Methods
Bioinformatics analysis
For each of the eight viral mRNA fragments (PB2, PB1, PA,
HA, NP, NA, M, NS), 20 full-length sequences from the NCBI
Influenza Virus Resource [41] were chosen arbitrarily for each of
the seven subtypes known to infect humans (H1N1, H1N2, H2N2,
H3N2, H5N1, H7N3, H9N2) resulting in a total of about 2000
sequences analyzed. Sequences were aligned and analyzed for
conserved sequences fulfilling the requirement for a SOFA-HDV-
Rz target (HG*N*6-N3–6-N*9–12; H=A, C or T; N=A, T, G or
C; *=conserved nt). The sequence of the each candidate SOFA-
HDV-Rz designed was screened for the potential off-targeting on
human host mRNAs using the RiboSubstrate software [29] with
the Human NCBI build36.2 mRNAs database (ftp://ftp.ncbi.nih.
gov/genomes/H_sapiens/RNA) and standard settings (BS mis-
match=3; Minimum spacer length=1; Maximum spacer
length=10).
RNA synthesis
DNA oligonucleotides (IDT) with the following sequences were
used for the synthesis of SOFA-HDV-Rz: a specific SOFA-HDV-
Rz_fwd 59-TAATACGACTCACTATAGGGCCAGCTAGTTT-
BS9–12-BL4-CAGGGTCCACCTCCTCGCGGT-P17-GGGCAT-
CCGTTCGCG-39 (where BS, BL and P1 indicate the biosensor,
the blocker sequence and the P1 recognition domain, respectively;
T7 promoter is in the underlined region) and the universal SOFA-
HDV-Rz_rev 59-CCAGCTAGAAAGGGTCCCTTAGCCATC-
CGCGAACGGATGCCC -39. The double-stranded SOFA-H-
DV-Rz DNA was obtained after a filling reaction, and SOFA-HDV
Rz RNA was synthesized by a run-off transcription from PCR
products as described previously [25]. Briefly, transcriptions were
performed in the presence of purified T7 RNA polymerase (10 mg)
[42] as described previously [43], RNaseOUT (20 U, Invitrogen),
pyrophosphatase (0.01 U, Roche Diagnostics, Laval, QC, Canada)
and PCRproduct(2–5 mM) ina buffercontaining 80 mMHEPES-
KOH pH 7.5, 24 mM MgCl2, 2 mM spermidine, 40 mM DTT,
5 mM of each NTP in a final volume of 100 ml at 37uC for 2 h.
Upon completion, the reaction mixtures were treated with DNase
RQ1 (Amersham Biosciences, Piscataway, NJ) at 37uC for 20 min,
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then precipitated with ethanol.
Influenza cDNAs of H1N1 A/USSR/90/77 were subcloned in
pBluescript SK+ (Stratagene). RNA substrates were synthesized by
run-off transcription from SacII (NEB) linearized pBluescript-SK+
containing the appropriate cDNA template with the MEGAscript
T7 transcription kit (Ambion) according to the manufacturer
instructions. For the production of internally radiolabelled
substrate, the transcription reactions were performed in the
presence of 5 uM UTP and 6 pmol of a-
32P UTP (3000 Ci/
mmol, Perkin Elmer). Upon completion, the reaction mixtures
were treated with TURBO DNase (2 U, Ambion) at 37uC for
20 min. The RNA products were fractionated by denaturing
polyacrylamide gel electrophoresis (PAGE; 19 : 1 ratio of
acrylamide to bisacrylamide). The reaction products were
visualized by either UV shadowing or autoradiography. The
bands corresponding to the correct size were cut out and the
transcripts eluted overnight at 4uC. The 39 radiolabelled substrates
were generated in a ligation reaction performed with 50 pmol of
purified RNA, 30 pmol of
32PcP (3000 Ci/mmol, Perkin-Elmer),
20 U of RNaseOUT (Invitrogen) and purified T4 RNA ligase
(10 mg) in a buffer containing 50 mM Tris-HCl pH 7.8, 10 mM
MgCl2, 1 mM ATP, 10 mM DTT and 10% DMSO in a final
volume of 10 mLa t3 7 uC for 1 h. The products were fractionated
by denaturing PAGE, isolated and purified as described above.
In vitro cleavage assays
SOFA-HDV-Rz cleavage assays were performed in the
presence of 1 pmol of either 39- (NS substrate) or internally
32P-
labelled target mRNA (all other substrates) mixed with SOFA-
HDV-Rz (20 pmol) in a 20 mL mixture containing 50 mM Tris-
HCl, pH 7.5, and 10 mM MgCl2 and then incubated at 37uC for
2 h. The reactions were stopped by the addition of denaturing
loading buffer, separated on denaturing 5% PAGE gels, and then
analyzed by autoradiography on a Phosphorscreen (GE Health-
care).
Construction of pDUAL-JU and introduction of
SOFA-HDV-Rz and target Influenza mRNAs
The tet-responsive Pol II promoter Ptight was amplified from
the plasmid pTRE-Tight (Clontech Laboratories, Inc.), cloned in
pGEM-T (Promega) and subcloned in pBudCE4.1 (Invitrogen)
with the added restriction sites BbsI and NheI (NEB). The Pol III
promoter PhHI was amplified from the plasmid psiRNA-
hH1GFPzeo (InvivoGen) and cloned in the engineered plasmid
with the added restriction sites BspHI and SbfI. The two
promoters inserted in the resulting pDUAL-JU vector were
sequenced in both directions to assure that the correct sequences
were cloned. The different SOFA-HDV-Rz were PCR amplified
and inserted after the PhHI promoter of pDUAL-JU using added
BbsI restriction sites. The PCR products containing the respective
targets were cloned with added MluI and NotI restriction sites
after the Ptight promoter of the pDUAL-JU containing or not the
DNA sequence of a SOFA-HDV-Rz. The resulting plasmids were
sequenced to verify both the sequences of the SOFA-HDV-Rz and
the substrate.
Cell culture and DNA transfection
HEK-293 cells (obtained from the American Type Culture
Collection; CRL-1573) were grown in Dulbecco’s modified Eagle’s
medium (DMEM, Wisent) supplemented with 10% fetal bovine
serum (FBS, Wisent), 1 mM sodium pyruvate and 2 mM L-
glutamine at 37uC in 5% CO2. Cells were transfected with pTET-
ON (Clontech) using Lipofectamine 2000 (Invitrogen), as per the
manufacturer’s instructions. This pTET-ON vector is used to
transform cells so they can express the Tet-responsive transacti-
vator. Briefly, cells were seeded into 10 cm-dishes plates at 36106
cells/well and transfected with 24 mg of plasmid DNA that was
complexed with the provided transfection reagent. They were then
selected for resistance to G-418 at a final concentration of 600 mg/
mL. G-418-resistant colonies were isolated and screened for the
highest fold-induction (highest expression with lowest background)
with the luciferase reporter assay kit provided by the manufacturer
(Clontech).
HEK-293 cells expressing the Tet-responsive element were
transfected with the different pDUAL-JU constructs containing
the target with or without SOFA-HDV-Rz. Briefly, cells were
seeded into 12-well plates at 2610
5 cells/well and transfected with
1 mg of plasmid DNA that was complexed with Lipofectamine
2000. The target mRNA expression was induced for 4 or 20 h
with doxycycline (Sigma) at a final concentration of 975 ng/mL
prior to RNA extraction with TriPur (Roche) according to the
manufacturer instructions.
Ribonucleic Protection Assay and Northern Blot
Hybridizations
For the ribonucleic protection assay (RPA), 5 mg of total RNA
extract was processed with the RPA III
TM Ribonuclease
Protection Assay Kit (Ambion) as recommended by the manufac-
turer. Probes with 39 and 59 overhangs of 15 nucleotides were
transcribed from PCR products of pBluescript plasmids containing
the fragments described above.
Northern blot analyses of 10 mg total RNA extract were
performed as described previously [25]. The probes to detect
the Influenza target or the control Zeo
R mRNA were obtained
by a T3 RNA polymerase-based transcription in the presence
of 30 pmol of a-
32P UTP (3000 Ci/mmol, Amersham
Biosciences) on the pBluescript plasmids containing the
fragments described above, and the b-actin RNA probe was
transcribed from pTRI-B-Actin-Mouse (Ambion). The plas-
mids were digested to yield run-off transcription products
ranging from 134 nts to 503 nts in length. All probes were
prepared with the MAXIscript T3 transcription kit (Ambion)
according to the manufacturer instructions, and hybridizations
were carried out for 16–18 h at 60uC. The membranes were
then washed and analyzed by autoradiography on a Phos-
phorscreen (GE Healthcare).
Evaluation of antiviral activity in cellulo
Madin-Darby canine kidney (MDCK) cells (obtained from the
American Type Culture Collection; CCL-34) were seeded in 12-
well plates at 4610
5 cellules/ml in DMEM supplemented with 5%
FBS. The next day, the cells were transfected with 0.75 mg of two
pDUAL-JU plasmids coding for different ribozymes, but free of
any substrate sequence, using Lipofectamine 2000. On day 2, the
medium was replaced by DMEM with 2 mg/ml TPCK-trypsin
(Sigma), and the cells were infected with H1N1 influenza A/
Puerto Rico/8/34 (A/PR/8/34) at a multiplicity of infection
(MOI) of 0.1. After 10 h, cells were detached using Versene
(Invitrogen), washed once with phosphate-buffered saline (PBS,
Invitrogen), and fixed with Cytofix/Cytoperm (BD Biosciences).
After incubation with a mouse monoclonal antibody against
influenza hemagglutinin (clone C102; Santa Cruz Biotech) in
combination with a goat anti-mouse Alexa647-labeled secondary
antibody (Invitrogen), the percentage of infected cells was
quantified by flow cytometry.
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Groups of three to five 6 week-old female BALB/c mice
(Charles River) were instilled intranasally with 10 mg each of the
same plasmid combinations used for the in vitro replication
experiments, or 20 mg of pEGFP-N1 (Clontech) as transfection
control, using In Vivo-jetPEI
TM (Polyplus Transfection) as
transfection reagent according to the manufacturer’s instructions,
followed intranasal infection with 10
5 TCID50 of H1N1 A/PR/8/
34 6 h later. Animals were monitored daily for signs of disease. To
assess clinical disease severity, a three-step grading system was
used.
For Posture, 0 represented normal, 1 slow movement, and 2
back curved and tousled fur. Activity was graded 0 for normal, 1
for calm, and 2 for inactive, and weight loss was classified as 0 for 0
to 15% loss, 1 for 15 to 20% loss, or 2 for more than 20%.
In a second experiment, all animals were euthanized on day 1
after infection, the lungs were harvested, and virus titers were
determined by limited dilution method and expressed as TCID50.
The Mann-Whitney test was used for statistical analyses. All
experiments were approved by the institutional animal care and
use committee of the Institut National de la Recherche
Scientifique-Institut Armand-Frappier (#0705-04).
Supporting Information
Figure S1 Schematic representation of the plasmid
designed to simultaneously express a SOFA-HDV-Rz
and the corresponding target mRNA. SOFA-HDV-Rz are
under the control of a cellular RNA polymerase III promoter,
while viral mRNAs are expressed using a Tet-inducible Pol II
promoter.
(TIF)
Table S1 Predicted specificity of the selected SOFA-
HDV-Rz.
(EPS)
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